China updates pharmacopoeia; India harmonizes

The 2010 edition of China's Pharmacopoeia is set to hit the streets October 1. Some 40 percent of the new edition encompasses "new types of drugs," according to a report.

The update is expected to improve the international competitiveness of drugs made in China, says a government official in the report. It includes "improvements" on 70 percent of existing medications. The new edition also targets drugmakers that have "advanced technology and quality control."

Separately, India's pharmacopoeia commission says it wants to harmonize chapters with global standards set by the Pharmacopoeial Discussion Group. The commission met recently with United States Pharmacopoeia representatives regarding plans to align the Indian pharmacopeia with those of the U.S., Europe and Japan.

- here's the China's pharmacopoeia article
- see this article on India's efforts

 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.